Ian N Foltz
Overview
Explore the profile of Ian N Foltz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foltz I, Gaida K, Wong H, Ng M, Busch M, Liu J
J Inflamm Res
. 2024 Dec;
17:10627-10640.
PMID: 39670154
Purpose: ABP 654 is the first FDA-approved interchangeable biosimilar for ustekinumab reference product (RP). To support the totality of evidence (TOE), in vitro pharmacology studies were conducted in peripheral blood...
2.
Seo N, Guan X, Wang T, Chung H, Wikstrom M, Padaki R, et al.
Ophthalmol Ther
. 2024 Mar;
13(5):1303-1320.
PMID: 38507189
Introduction: ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders. This study was designed to provide a...
3.
Woodall D, Thomson C, Dillon T, McAuley A, Green L, Foltz I, et al.
Anal Chem
. 2023 Oct;
95(42):15477-15485.
PMID: 37812809
The binding affinity of monoclonal antibodies (mAbs) for their intended therapeutic targets is often affected by chemical and post-translational modifications in the antigen binding (Fab) domains. A new two-dimensional analytical...
4.
Kielczewska A, DAngelo I, Amador M, Wang T, Sudom A, Min X, et al.
J Biol Chem
. 2022 Jan;
298(2):101533.
PMID: 34973336
Therapeutic antibody development requires discovery of an antibody molecule with desired specificities and drug-like properties. For toxicological studies, a therapeutic antibody must bind the ortholog antigen with a similar affinity...
5.
Ellwanger D, Wang S, Brioschi S, Shao Z, Green L, Case R, et al.
Proc Natl Acad Sci U S A
. 2021 Jan;
118(3).
PMID: 33446504
Triggering receptor expressed on myeloid cells 2 (TREM2) sustains microglia response to brain injury stimuli including apoptotic cells, myelin damage, and amyloid β (Aβ). Alzheimer's disease (AD) risk is associated...
6.
Walker K, Foltz I, Wang T, Salimi-Moosavi H, Bailis J, Lee F, et al.
J Biol Chem
. 2020 Jun;
295(30):10446-10455.
PMID: 32518163
Transthyretin (TTR) is an abundant homotetrameric serum protein and was selected here for engineering higher-valency molecules because of its compact size, simple structure, and natural propensity to tetramerize. To demonstrate...
7.
Jassem S, Wang W, Sweet H, Manoukian R, Chow V, Kanakaraj P, et al.
Pharm Res
. 2019 Nov;
36(12):177.
PMID: 31696314
Purpose: The in vitro and in vivo pharmacologic assessment of ABP 980 similarity to its reference product is intended to compare the activity of ABP 980 and trastuzumab and support...
8.
Killion E, Wang J, Yie J, Shi S, Bates D, Min X, et al.
Sci Transl Med
. 2018 Dec;
10(472).
PMID: 30567927
Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) has been identified in multiple genome-wide association studies (GWAS) as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO)....
9.
Sudom A, Talreja S, Danao J, Bragg E, Kegel R, Min X, et al.
J Biol Chem
. 2018 May;
293(32):12634-12646.
PMID: 29794134
Triggering receptor expressed on myeloid cells 2 (TREM2) is an immune receptor expressed on the surface of microglia, macrophages, dendritic cells, and osteoclasts. The R47H TREM2 variant is a significant...
10.
Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, et al.
J Biol Chem
. 2018 Mar;
293(32):12620-12633.
PMID: 29599291
Triggering receptor expressed on myeloid cells 2 (TREM2) is an orphan immune receptor expressed on cells of myeloid lineage such as macrophages and microglia. The rare variant R47H TREM2 is...